

## Innovative Medicines Initiative 2 funding opportunities June 2020

The **Innovative Medicines Initiative (IMI)** has now launched its final **Call for proposals under IMI2**. The Calls give researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

### Why apply?

- Obtain **research funding**
- Take part in **scientifically excellent, patient-centric** research
- Join unique consortia involving **top teams** from industry, academia, SMEs, regulators, and others
- Benefit from the **expertise, databases, and infrastructures** of consortium partners
- Boost the **visibility and status** of your organisation in Europe and globally and gain **access to new markets**

### IMI2 – Call 22

IMI2 – Call 22 was launched on 23 June 2020 and is a single-stage Call for proposals designed to support research activities that will build on, and add value to, results from certain ongoing IMI2 projects. It has one topic:

- Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities

**Read the topic text:**

[bit.ly/imi2call22](https://bit.ly/imi2call22)

**Deadline for proposals:**

29 September 2020

### IMI2 – Call 23

IMI2 – Call 23 was launched on 23 June 2020 and is a standard, two-stage Call for proposals. It includes the following topics:

- Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance  
This topic is part of IMI's Antimicrobial Resistance (AMR) Accelerator programme.
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence

**Read the topic texts:**

[bit.ly/imi2call23](https://bit.ly/imi2call23)

**Deadline for short proposals:**

29 September 2020

## How to apply

- The rules and details of how to apply can be found via the Call pages of the IMI website.
- Find out more about both Calls for proposals via our webinars – see [bit.ly/2zz0M2D](http://bit.ly/2zz0M2D)
- Follow IMI's tips for applicants – see [bit.ly/IMItips](http://bit.ly/IMItips)
- Get advice on finding project partners on our partner search page – [bit.ly/IMIfindpartners](http://bit.ly/IMIfindpartners)

## About the Innovative Medicines Initiative

At IMI, we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

We do this by facilitating collaboration between the key players involved in healthcare research.

We are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.

Since our launch in 2008, we have launched over 125 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.

### Stay in touch

Visit the IMI website:

[www.imi.europa.eu](http://www.imi.europa.eu)

Sign up to the IMI Newsletter:

[bit.ly/IMINewsletter](http://bit.ly/IMINewsletter)

Follow us on Twitter:

[@IMI\\_JU](https://twitter.com/IMI_JU)

Join the IMI group on LinkedIn:

[bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)

E-mail us:

[infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)

Get support:

[bit.ly/IMIsupport](http://bit.ly/IMIsupport)